Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.GRCE · Entity 7266 | Chief Medical Officer | August 28, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date August 28, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2036-08-27 | Direct | 54,690 |
Reported balance
After 2026-08-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 54,690 · Balance 54,690 F1: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PDS Biotechnology Corp
Report date March 15, 2019 · Filed March 18, 2019
Section 16 reporting ended · disclosed 2019-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 580,602 |
Reported balance
After 2019-03-15 transaction · row 1
1 source rowRow 1 · 2019-03-15 · Exercise / conversion · Acquired 10,000 · Balance 580,602 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-15 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. |
| Common StockSEC Table I · non-derivative | Indirect401(K) Plan | 7,127.6 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,127.6 |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.
F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.
F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Sep 1, 2026 20:05 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 54,690 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001140361-26-035317 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,690 Underlying: Common Stock · 54,690 shares Expires 2036-08-27 F1 · derivative.exercise_date: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date. Read SEC document |
| April 14, 2025 Filed Apr 17, 2025 00:58 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-25-014265 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-04-14 F1 · derivative.exercise_date: This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:19 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 25,380 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0000950170-24-056083 · ownership.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,380 Underlying: Class A Common Shares · 25,380 shares Expires 2034-05-06 F1 · derivative.exercise_date: Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:34 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014997 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A Common Shares · 60,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:59 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011943 · form4.xml · derivative · entry 3 Macdonald R. Loch · CIK 0001653008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F3 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F4 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:59 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011943 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 12:12 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025379 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:35 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021589 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| March 22, 2018 Filed Mar 22, 2018 20:03 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 2,500 | $16.41 | $41,025.00 |
DisclosureSEC source: 0001127602-18-012504 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.25 to $16.56 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2018 Filed Mar 21, 2018 15:34 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 2,500 | $16.52 | $41,300.00 |
DisclosureSEC source: 0001127602-18-012359 · form4.xml · nonDerivative · entry 3 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,102 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.42 to $16.58 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 15:34 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 5,000 | $16.47 | $82,350.00 |
DisclosureSEC source: 0001127602-18-012359 · form4.xml · nonDerivative · entry 2 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.86 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 15:34 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 2,500 | $16.66 | $41,650.00 |
DisclosureSEC source: 0001127602-18-012359 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.97 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2018 Filed Feb 22, 2018 22:00 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 2,500 | $14.49 | $36,225.00 |
DisclosureSEC source: 0001127602-18-007774 · form4.xml · nonDerivative · entry 3 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,102 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.23 to $14.76 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 22:00 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 5,000 | $13.82 | $69,100.00 |
DisclosureSEC source: 0001127602-18-007774 · form4.xml · nonDerivative · entry 2 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.68 to $14.05 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:00 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | SaleCommon Stock | 5,000 | $13.75 | $68,750.00 |
DisclosureSEC source: 0001127602-18-007774 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.66 to $13.86 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 19:36 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (right To Purchase) · Derivative | 110,000 | $8.86 Strike: $8.86 | $974,600.00 |
DisclosureSEC source: 0001127602-17-011770 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-03-13 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 110,000 shares of Common Stock, will become exercisable on February 17, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| January 23, 2017 Filed Jan 25, 2017 14:35 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionStock Option (right To Purchase) · Derivative | 25,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001127602-17-002309 · form4.xml · derivative · entry 2 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,504 Underlying: Common Stock · 25,000 shares Expires 2023-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 100,504 shares of Common Stock, became exercisable on June 1, 2014, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| January 23, 2017 Filed Jan 25, 2017 14:35 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionCommon Stock | 25,000 | $2.04 | $51,000.00 |
DisclosureSEC source: 0001127602-17-002309 · form4.xml · nonDerivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.